

Anti-Mouse CD69 PE

Catalog Number :11712-60 RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Clone: H1.2F3Format/Conjugate: PEConcentration: 0.2 mg/mlReactivity: MouseLaser: Blue (488nm), Yellow/Green (532-561nm)Peak Emission: 578nmPeak Excitation: 496nmFilter: 585/40Brightness (1=dim,5=brightest): 5Isotype: Armenian Hamster IgGFormulation: Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.Storage: Product should be kept at 2-8°C and protected from prolonged exposure to light.Applications: FC

Description

The H1.2F3 monoclonal antibody specifically reacts with human CD69, the 27-33 kDA type II transmembrane protein also known as the very early activation antigen (VEA) or the activation inducer molecule (AIM). It is expressed as a disulfide-linked dimer on B cells, T cells, NK cells, platelets, eosinophils, and neutrophils. It increases in expression upon cell activation and seems to serve a role as a signaling receptor.

Preparation & Storage

The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ug per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

References

1.Marzio, R., Jirillo, E., Ransijn, A., Mauel, J., Corradin, S. B. (1997). Expression and function of the early activation antigen CD69 in murine macrophages.; Journal of leukocyte biology,; 62(3), 349-355.

2. Yokoyama, W. M., Koning, F., Kehn, P. J., Pereira, G. M., Stingl, G., Coligan, J. E., Shevach, E. M. (1988). Characterization of a cell surfaceexpressed disulfide-linked dimer involved in murine T cell activation.; The Journal of Immunology,; 141(2), 369-376.

3. Sobel, E. S., Yokoyama, W. M., Shevach, E. M., Eisenberg, R. A., Cohen, P. L. (1993). Aberrant expression of the very early activation antigen on MRL/Mp-lpr/lpr lymphocytes.;The Journal of Immunology,;150(2), 673-682.